Josh Siepel

Big Pharma, Little Science? A Bibliometric Perspective on Big Pharma’s R&D Decline

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms (Big Pharma) during the period 1995–2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by Big Pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that Big Pharma are increasingly becoming ‘network integrators’ rather than the prime locus of drug discovery.

From Funding Gaps to Thin Markets: UK Government Support for Early-Stage Venture Capital

Hybrid venture capital funds have a small positive impact on firm performance. This paper explores the implications of this finding for public policy in the United Kingdom.

Just how difficult can it be counting up R&D funding for emerging technologies (and is tech mining with proxy measures going to be any better)?

Decision makers considering policy or strategy related to the development of emerging technologies expect high quality data on the support for different technological options in order to track trends and allocate resources. A natural starting point would be R&D funding statistics. This paper explores the limitations of such aggregated data in relation to the substance and quantification of funding for emerging technologies. Using biotechnology as an illustrative case, we test the utility of a novel taxonomy to demonstrate the endemic weaknesses in the availability and quality of data from public and private sources. Using the same taxonomy, we consider the extent to which tech-mining presents an alternative, or potentially complementary, way to determine support for emerging technologies using proxy measures such as patents and scientific publications. We find that using proxy measures provides additional visibility of technological emergence and suggest these are a useful complement to financial data.

Growth processes of high-growth firms as a four-dimensional chicken and egg

This article investigates whether high-growth firms grow in different ways from other firms. Specifically, we analyze how firms grow along several dimensions (growth of sales, employment, assets, and operating profits) using Structural Vector Autoregressions. Causal relations are identified by using information contained in the (non-Gaussian) growth rate distributions. For most firms, the growth process starts with employment growth, which is then followed by sales growth, then growth of operating profits, and finally growth of assets. In contrast, high growth firms put more emphasis on growth of operating profits driving other dimensions of growth, with employment growth occurring at the end.

Long-run drivers of growth for UK high technology firms

Despite the importance of high technology firms to the global economy, relatively little is known about factors contributing to these firms’ long-run growth. We examine these factors using a unique longitudinal dataset combining two waves of detailed surveys of 345 UK high tech firms with performance data from UK official datasets. Overall we conclude that the early strategic decisions made by firms have long-run impacts on their subsequent growth, and we suggest that policy measures targeted at shortfalls faced by these firms may have positive long-term consequences.

Understanding Long-Run Growth and Survival of High-Tech Ventures

Despite the importance of high technology firms to the UK’s economy, relatively little is known about factors contributing to these firms’ long-run growth and survival. We examine these factors using a unique longitudinal dataset combining two waves of detailed surveys of 345 UK high tech firms and performance and survival data. We explore factors contributing to the performance and survival of these firms. Our results show that long-term survival rates are near two thirds for the firms in our sample, and that performance within the sample is skewed by a limited number of high performing firms. Overall we conclude that the early strategic decisions made by firms have long-run impacts on their survival and growth, and we suggest that policy measures targeted at shortfalls faced by these firms may have positive long-term consequences.